Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

更换25.jpg

Litchlab: Advancing RNA Therapeutics with Cutting-Edge Liposomal Technology

RNA-based therapies, such as siRNA, mRNA, and ASOs, have emerged as groundbreaking treatments for genetic disorders, cancers, and infectious diseases. However, the delivery challenge remains a major barrier—naked RNA molecules are highly unstable, easily...

更换10.jpg

Litchlab Expands Advanced Lipid Synthesis & Modification Capabilities to Drive Next-Gen Drug Delivery

Litchlab, a global leader in lipid-based drug delivery solutions, has announced the expansion of its advanced lipid synthesis and modification capabilities. With cutting-edge technologies and an innovative approach, Litchlab provides customized lipid solutions...

更换29.jpg

FDA Approves Onivyde Combination Therapy: Litchlab Advances Liposomal Precision Oncology

The U.S. Food and Drug Administration (FDA) has approved liposomal irinotecan (Onivyde) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX regimen) as a first-line treatment for metastatic pancreatic adenocarcinoma. This landmark approval...

更换16.jpg

Litchlab Advances PEGylation Technology to Enhance Drug Delivery and Biocompatibility

In modern biopharmaceuticals, PEGylation has emerged as a key strategy for optimizing drug delivery, improving therapeutic efficacy, and prolonging drug half-life. As a global leader in CDMO (Contract Development and Manufacturing Organization) services, Litch...

更换12.jpg

Litchlab: Advancing Liposomal Targeted Delivery Technology for Precision Drug Development

Liposomal Technology: A Breakthrough Drug Delivery PlatformIn the era of precision medicine and rapid advancements in nanopharmaceutical technology, liposomes have emerged as a key platform for next-generation drug delivery due to their ability to enhance bioa...

荧光5.jpg

Litchlab Unveils Advanced Polymeric Microsphere Technology for Precision Drug Delivery and Long-Acting Therapies

As the global pharmaceutical industry increasingly seeks efficient, safe, and controlled drug delivery systems, Litchlab is at the forefront with its cutting-edge polymeric microsphere technology. This innovation enables long-acting formulations, controlled dr...

上一页 3 4 5 6 7 下一页